Is this your company? Get featured or correct your listing →
Recent changes
- Oct 19, 2026Oct 19, 2026Silence Therapeutics Sells For $1.3B | 130% Premium From Merck KGaA Pulse story
Latest Pulse
- Oct 19, 2026Silence Therapeutics Sells For $1.3B | 130% Premium From Merck KGaAMerck KGaA, Darmstadt, Germany agreed to acquire Silence Therapeutics in an all-cash deal worth about $1.3 billion in equity value, paying $20.00 per ADS -- a 130% premium to Friday's close -- to get full control of its lead siRNA drug Divesiran.→
- Oct 19, 2026Nouscom Raises $135M To Push Cancer-Prevention Vaccine Toward ApprovalSwiss biotech Nouscom raised $135M (€120M) in a Series D co-led by M Ventures, Merck KGaA's venture arm, and Revelation Partners, to fund a global trial of cancer-prevention vaccine NOUS-209 in Lynch syndrome carriers.→
- Jul 7, 2026Cyllene Therapeutics Raises €33M for Gene TherapyCyllene Therapeutics, formerly EG 427, raised €33 million co-led by Merck Ventures to advance its HSV-1 gene-therapy platform toward treating neurogenic bladder conditions.→